No Data
No Data
Cantor Fitzgerald Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $104
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $75
New Analyst Forecast: $VKTX Given 'Overweight' Rating
Viking Therapeutics Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Initiates Coverage On Viking Therapeutics With Overweight Rating, Announces Price Target of $104
Leadership in Action: Max Roix Promoted to Advisor for Viking M&A's Florida Division